Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: Why have they failed in lowering coronary heart disease risk?

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 259-264

  Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

ApoA I; CETP; CETP inhibitors; Coronary heart disease; HDL cholesterol

Indexed keywords

ABC TRANSPORTER G1; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ESTERIFICATION; HUMAN; IMMUNOBLOTTING; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STOICHIOMETRY;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; HUMANS; LIPID METABOLISM; PROTEIN BINDING; QUINOLINES; SULFHYDRYL COMPOUNDS; TREATMENT FAILURE; TRIGLYCERIDES;

EID: 84880133007     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283612454     Document Type: Review

References (49)

1. Inazu A, Brown ML, Hesler CB, et al. Increased high density lipoprotein levels caused by acommon cholesteryl-transfer protein gene mutation. NEngl JMed 1990; 323:1234-1238. (Pubitemid 20366528)
2. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000; 11:589-596.
3. Asztalos BF, Horvath KV, Kajinami K, et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004; 45:448-545.
4. Miwa K, Inazu A, Kawashiri M, et al. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 2009; 402:19-24.
5. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuated atherosclerosis in rabbits. Nature 2000; 406:203-207. (Pubitemid 30469005)
6. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose response study. Circulation 2002; 105:2159-2165. (Pubitemid 34517159)
7. Lüscher TF, Taddei S, Kaski JC, et al., Dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33:857-865.
8. Schwartz GG, Olsson AG, Abt M, et al., Dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-2099.
9. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-1515. (Pubitemid 38477775)
10. Clark RW, Surfin TA, Ruggeri RB, et al. Raising high-density lipoproteins in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24: 490-497. (Pubitemid 38326143)
11. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007; 48:1263-1272. (Pubitemid 47312028)
12. Barter PJ, Caulfield M, Eriksson M, et al., ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. (Pubitemid 350146106)
13. Nissen SE, Tardif JC, Nicholls SJ, et al., ILLUSTRATE Investigators. Effects of torcetrapib on progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316. (Pubitemid 46513296)
14. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008; 118:2506-2514.
15. Kastelein JJ, van Leuven SI, Burgess L, et al., RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterole-mia. N Engl J Med 2007; 356:1620-1630. (Pubitemid 46631671)
16. Bots ML, Visseren FL, Evans GW, et al., RADIANCE 2 Investigators. Torce-trapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): a randomized, double-blind trial. Lancet 2007; 370:107-108.
17. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009; 150:2211-2219.
18. Krishna R, Bergman AJ, Jin B, et al. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharm 2009; 49:80-87.
19. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadminis-tered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157:352-360.
20. Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
21. Davidson M, Liu SX, Barter P, et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res 2013; 54:467-472.
22. Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res 2012; 53:540-547.
23. Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52:2169-2176.
24. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099-2109.
25. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipopro-tein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005; 25:1057-1064. (Pubitemid 40627855)
26. Brousseau ME, Millar JS, Diffenderfer MR, et al. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein (apo) A-II-containing HDL subspecies and apoA-II metabolism. J Lipid Res 2009; 50:1456-1462.
27. Millar JS, Brousseau ME, Diffenderfer MR, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism. Arterioscler Thromb Vasc Biol 2006; 26:1350-1356. (Pubitemid 44305381)
28. Millar JS, Brousseau ME, Diffenderfer MR, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. J Lipid Res 2008; 49:543-549.
29. Diffenderfer MR, Brousseau ME, Millar JS, et al. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism. J Lipid Res 2012; 53:1190-1199.
30. Tall AR. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 2009; 104 (10 Suppl.):39E-45E.
31. Ginsberg HN, Reyes-Soffer G, Millar J, et al. Effects of anacetrapib on apolipoprotein A-I and A-II metabolism and high density lipoprotein sub species. Eur Soc Cardiol 2012 [abstract].
32. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24:2181-2187. (Pubitemid 39482449)
33. Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25:2185-2191. (Pubitemid 41416319)
34. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha-1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:847-852. (Pubitemid 36566176)
35. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographi-cally defined disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2008; 28:575-579.
36. Asztalos BF, LeMaulf F, Dallal GE, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high density lipoproteins. Am J Cardiol 2007; 99:681-685.
37. Lamon-Fava S, Diffenderfer MR, Barrett PHR, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008; 28:1672-1678.
38. Schaefer EJ, Santos RD, Asztalos B. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 2010; 21:289-297.
39. Clark RW, Ruggieri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester protein inhibitors, including mechanism of action. J Lipid Res 2006; 47:537-552. (Pubitemid 43345595)
40. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cho-lesteryl ester transfer protein inhibitors. J Lipid Res 2010; 51:2739-2752.
41. Liu S, Mistry A, Reynolds JM, et al. Crystal structures of cholesteryl ester transfer & protein in complex with inhibitors. J Biol Chem 2012; 287:37321-37329. An important study examining the crystal structures of CETP inhibitors and the complex they form with CETP.
42. Han S, Levoci L, Fischer P, et al. Inhibition of cholesteryl ester transfer protein & by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein. Biochim Biophys Acta 2012; 1831:825-833.
43. Vaisar T. Proteomics investigations of HDL: challenges and promise. Curr Vasc Pharmacol 2012; 10:410-421.
44. Riwanto M, Rohrer L, Roschitzki B, et al. Altered activation of endothelial anti and pro-apoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of HDL-proteome remodeling. Circulation 2013; 127:891-904; doi: 10.1161/CIRCULATIONAHA.112.108753.
45. Cubedo J, Padró T, Alonso R, et al. Differential proteomic distribution of TTR (prealbumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis 2012; 222:263-269.
46. Tölle M, Huang T, Schuchardt M, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 2012; 94:154-162. A study clearly documenting increased serum amyloid A protein in HDL converts HDL from anti-inflammatory to proinflammatory HDL.
47. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23:934-947.
48. Alwaili K, Bailey D, Awan Z, et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 2012; 1821:405-415.
49. Vazquez E, Sethi AA, Freeman L, et al. High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women. Am J Cardiol 2012; 109:527-532.